ROS1-rearranged non-small cell lung carcinoma

From Libre Pathology
Revision as of 11:22, 31 December 2019 by Michael (talk | contribs) (→‎Molecular)
Jump to navigation Jump to search
Micrograph showing a ROS1-positive adenocarcinoma of the lung. ROS1 immunostain.

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]





  • Most common pattern varies by specimen type:[4]
    • Biopsy specimens: solid pattern most common.
    • Resection specimens: acinar pattern most common.



  • ROS1 +ve.



  • ROS1 rearrangements can be demonstrated with dual-colour break apart FISH probes.[5]

See also


  1. Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  2. "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
  3. "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. //
  4. 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. //
  5. "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. November 2016. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. //